Sermorelin: what it is, what it costs, and who sells it

Sermorelin is a 29-amino-acid fragment of human GHRH, engineered to trigger the pituitary gland's own growth-hormone release the same way the body's natural hormone does. Its only FDA-approved brand, Geref, was approved in 1990 for diagnosing and treating growth-hormone deficiency in children — confirmed directly against FDA's own Drugs@FDA record, which lists both of Geref's applications as “Discontinued,” with FDA's own note that the withdrawal was not for safety or effectiveness reasons.

With no current label, sermorelin sold today is entirely a compounded product — pharmacy-prepared, not independently reviewed by FDA at the strength or purity a buyer actually receives — and it is what nearly every telehealth provider on the board below sells.

Sermorelin activates the GHRH receptor on the pituitary gland, stimulating the body's own pulsatile release of growth hormone rather than supplying growth hormone directly. The clinical evidence behind that mechanism is real but thin outside its original pediatric population: the best-controlled adult data comes from a 1997 trial of a closely related, stabilized GHRH analog — not sermorelin's own brand-name trials, which were pediatric — and even that trial found some effects (lean mass, well-being) appeared in men but not women at the same dose. Read the full, sourced walk-through of what sermorelin has and hasn't been shown to do, separated from anecdotal claims, in our sermorelin before-and-after evidence review.

Sermorelin sits in a different regulatory position than tirzepatide or semaglutide. Those two are FDA-approved drugs sold compounded under a narrow shortage exception; sermorelin has no current FDA-approved product at all, and its compounding today operates under the general 503A/503B pharmacy framework rather than a shortage-specific rule. FDA's current 503A nominated-substances list — checked directly, not summarized — does not list sermorelin in any of its three review categories, meaning it is not currently under active FDA compounding-safety evaluation the way some other peptides on this site are.

One status is unambiguous: sermorelin is named explicitly on the World Anti-Doping Agency's 2026 Prohibited List, banned at all times with no dose threshold or therapeutic-use exemption. For the full three-way regulatory and evidence comparison against ipamorelin and CJC-1295 — two compounds frequently sold alongside it under the same “GH peptide” marketing — see our full three-compound comparison.

Sermorelin's own recorded adverse events, from its thin trial and post-marketing record, are mild and mostly local: injection-site pain, transient flushing, and — in the best-controlled adult trial of a closely related analog — a transient lipid rise that resolved by the end of the study. FDA's adverse-event database carries only 58 sermorelin reports total, too few to compute a reliable incidence rate from either direction.

Because sermorelin has no current label of its own, the more informative safety source is tesamorelin's current FDA label — the one other GHRH-receptor drug still marketed. That label carries an explicit neoplasm warning (contraindicated in active malignancy) and states that the long-term consequences of sustained IGF-1 elevation are “unknown.” This page states that plainly rather than either alarming or reassuring: it is the closest marketed relative's label, not sermorelin's own. For the full evidence, including what the cancer-risk literature actually shows and two more-likely labelled effects (glucose intolerance, fluid retention), see our full sermorelin side-effects review. None of this is a recommendation for or against starting sermorelin — talk to a licensed clinician about your own situation.